Final Results of a Phase 1b Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

被引：3

作者：

Mims, Alice S. ^{[1
]}

Solh, Melhem ^{[2
]}

Saultz, Jennifer N. ^{[3
]}

Borate, Uma ^{[4
]}

Pemmaraju, Naveen ^{[5
]}

Borthakur, Gautam ^{[5
]}

Roboz, Gail J. ^{[6
]}

Powell, Ben ^{[7
]}

Matusow, Bernice ^{[7
]}

Halladay, Jason ^{[7
]}

Vali, Shireen ^{[7
]}

Hope, Chelsea L. ^{[7
]}

Kundu, Madan G. ^{[8
]}

Hsu, Ching ^{[8
]}

Watkins, Paul ^{[7
]}

Zhang, Chao ^{[7
]}

Walling, Jackie M. ^{[7
]}

Tsiatis, Athanasios C. ^{[7
]}

DeZern, Amy E. ^{[9
]}

机构：

[1] Ohio State Univ, Ctr Comprehens Canc, Clara Bloomfield Ctr Leukemia Outcomes Res, Columbus, OH 43210 USA

[2] Northside Hosp Canc Inst, Atlanta, GA USA

[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[4] Ohio State Univ, James Canc Ctr, Columbus, OH USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Cornell Univ, Weill Med Coll, Div Hematol Oncol, Dept Med, York, NY USA

[7] Plexxikon Inc, Berkeley, CA USA

[8] Daiichi Sankyo, Basking Ridge, NJ USA

[9] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21218 USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152040

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3420

引用

页数：6

共 50 条

[41] Efficacy analysis of different FLT3 inhibitors in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome
Swaminathan, Mahesh
Aly, Mai M.
Khan, Abdul Moiz
Share, Bayan Al
Dhillon, Vikram
Lalo, Enxhi
Ramos, Harry
Akers, Katherine G.
Kim, Seongho
Balasubramanian, Suresh
EJHAEM, 2023, 4 (01): : 165 - 173
[42] Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Jones, Jeffrey A.
Woyach, Jennifer
Awan, Farrukh T.
Maddocks, Kami J.
Whitlow, Thomas
Ruppert, Amy S.
Byrd, John C.
BLOOD, 2016, 128 (22)
[43] Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
Qi, Junyuan
Wei, Xudong
Li, Qiubai
Chang, Chukang
Zhou, Fuling
Huang, Jianying
Zhang, Yu
Xu, Chongyuan
Tang, Xiaowen
Jiang, Qian
Li, Junmin
Qin, Qun
He, Qun
Gao, Sujun
Liu, Liping
Chen, Zi
Yu, Min
Wang, Jing
Men, Lichuang
Wang, Hengbang
Ahmad, Mohammad
Yang, Dajun
Zhai, Yifan
Wang, Jianxiang
BLOOD, 2023, 142
[44] Phase 1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients with CD33+Relapsed or Refractory Acute Myeloid Leukemia
Swaminathan, Mahesh
Przespolewski, Amanda
Griffiths, Elizabeth A.
Thompson, James E.
Elshoury, Amro
Walinski, Wendy
Said, Meriem
Halliwell, Stephanie
Puff, Claire
Attwood, Kristopher
Wang, Eunice S.
BLOOD, 2021, 138
[45] Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage Dysplasia
Zeidan, Amer M.
Smith, B. Douglas
Carraway, Hetty E.
Gojo, Ivana
Sakoian, Sarah
Gore, Steven D.
DeZern, Amy E.
BLOOD, 2015, 126 (23)
[46] Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia
Vey, Norbert
Prebet, Thomas
Thalamas, Claire
Charbonnier, Aude
Rey, Jerome
Kloos, Ioana
Liu, Emily
Luan, Ying
Vezan, Remus
Graef, Thorsten
Recher, Christian
LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1880 - 1886
[47] Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Agrawal, Vaibhav
Croslin, Cindy
Beltran, Asuscena L.
Zhang, Jianying
Palmer, Joycelynne
Quy Huynh-Tran
Hernandez, Rochelle
Thomas, Sandra
Robbins, Marjorie
Aribi, Ahmed
Ali, Haris
Stein, Anthony S.
Budde, Elizabeth L.
Al Malki, Monzr M.
Marcucci, Guido
BLOOD, 2022, 140 : 6235 - 6236
[48] Phase 1B/2A safety, pharmacokinetics and pharmacodynamics study of fosciclopirox alone and in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia
Lin, Tara L.
Wood, Robyn
Ham, Tammy
Sullivan, Taegen
Dandawate, Prasad
Anant, Shrikant
Santaguida, Marianne T.
Toren, Paul
Jensen, Roy A.
Taylor, John A.
Baltezor, Michael Jay
Dalton, Michael
Meyer, Fred
McBride, John
Umbreit, Jay Nicholas
McCulloch, William
Vanderlaag, Kathryn
Wagner, Joseph
Weir, Scott James
Smith, B. Douglas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[49] Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study
Navada, Shyamala C.
Odchimar-Reissig, Rosalie
Reddy, E. Premkumar
Holland, James F.
Wilhelm, Francois
Silverman, Lewis R.
BLOOD, 2012, 120 (21)
[50] Twice Daily Fludarabine and Cytarabine Combination Is Effective in Patients with Relapsed/Refractory Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndromes, and Blast Phase Chronic Myeloid Leukemia
Daver, Naval
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Cortes, Jorge E.
Ravandi, Farhad
Plunkett, William
Gandhi, Varsha
Faderl, Stefan
O'Brien, Susan
Borthakur, Gautam
Kadia, Tapan
Burger, Jan A.
Konopleva, Marina
Brandt, Mark
Huang, Xuelin
Jabbour, Elias
BLOOD, 2011, 118 (21) : 1550 - 1550

← 1 2 3 4 5 →